Endonovo Therapeutics Appoints Dr. William Li as Strategic Advisor to the CEO
Los Angeles, CA, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announces it has appointed Dr. William Li as Strategic Advisor to the CEO. Dr. Li and Endonovo CEO Alan Collier will work collaboratively and strategically to explore growth strategies for Endonovo's contemplated market segments.
"Dr. Li is a globally recognized medical professional and a business visionary with a strong track record of success,” Collier stated. “Like us, he takes a long-term view of medical advances and believes industry can play a pivotal role in shaping the future. We look forward to working with Dr. Li to further extend our industry leadership by aligning Endonovo with each of the major market segments we can impact."
Dr. Li added, "I believe Endonovo has a strong technology platform with game changing potential as a player in the post-operative healing process, and is poised to go to the next level across a range of industry verticals. I look forward to working with Alan and the Endonovo team to evaluate the Company’s operational and strategic opportunities.”
Dr. Li is Chief Executive Officer and co-founder of the Angiogenesis Foundation. He trained in the lab of Dr. Judah Folkman, pioneer of the angiogenesis field, and has been actively engaged in angiogenesis research and clinical development for 30 years. Under Dr. Li’s leadership, the foundation has developed a unique social enterprise model based on value-creating collaborations with leading biopharmaceutical and medical device companies.
Dr. Li is actively engaged in identifying unmet needs in the healthcare space for which clinical and cost effective technology can offer beneficial solutions. He is a graduate of Harvard, and completed his medical residency training at Massachusetts General Hospital in Boston. He serves as advisor and consultant to leading global public and private companies.
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is a commercial-stage developer of noninvasive wearable Electroceuticals® therapeutic devices. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals® therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and central nervous system (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis. The Company's noninvasive Electroceutical® therapeutic device, SofPulse®, which uses pulsed short-wave radiofrequency at 27.12 MHz, has been FDA-cleared and CE marked for the palliative treatment of soft tissue injuries and post-operative pain and edema and has CMS national coverage for the treatment of chronic wounds. The Company's current portfolio of preclinical-stage Electroceuticals® therapeutic devices addresses chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The Company's noninvasive, wearable Electroceuticals® therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur. www.endonovo.com.
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.
Investor Relations Contact:
Endonovo Therapeutics, Inc. Mr. Andrew Barwicki 516-662-9461 Andrew@barwicki.com